Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study


Autoria(s): Bjerk, Sonja M.; Baker, Jason V.; Emery, Sean; Neuhaus, Jacqueline; Angus, Brian; Gordin, Fred M.; Pett, Sarah L.; Stephan, Christoph; Kunisaki, Ken M.; INSIGHT SMART Study Group; Casseb, Jorge Simão do Rosário
Data(s)

17/02/2014

17/02/2014

01/02/2013

Resumo

Background: Despite advances in HIV treatment, bacterial pneumonia continues to cause considerable morbidity and mortality in patients with HIV infection. Studies of biomarker associations with bacterial pneumonia risk in treated HIVinfected patients do not currently exist. Methods: We performed a nested, matched, case-control study among participants randomized to continuous combination antiretroviral therapy (cART) in the Strategies for Management of Antiretroviral Therapy trial. Patients who developed bacterial pneumonia (cases) and patients without bacterial pneumonia (controls) were matched 1:1 on clinical center, smoking status, age, and baseline cART use. Baseline levels of Club Cell Secretory Protein 16 (CC16), Surfactant Protein D (SP-D), C-reactive protein (hsCRP), interleukin-6 (IL-6), and d-dimer were compared between cases and controls. Results: Cases (n = 72) and controls (n = 72) were 25.7% female, 51.4% black, 65.3% current smokers, 9.7% diabetic, 36.1% co-infected with Hepatitis B/C, and 75.0% were on cART at baseline. Median (IQR) age was 45 (41, 51) years with CD4+ count of 553 (436, 690) cells/mm3. Baseline CC16 and SP-D were similar between cases and controls, but hsCRP was significantly higher in cases than controls (2.94 mg/mL in cases vs. 1.93 mg/mL in controls; p = 0.02). IL-6 and d-dimer levels were also higher in cases compared to controls, though differences were not statistically significant (p-value 0.06 and 0.10, respectively). Conclusions: In patients with cART-treated HIV infection, higher levels of systemic inflammatory markers were associated with increased bacterial pneumonia risk, while two pulmonary-specific inflammatory biomarkers, CC16 and SP-D, were not associated with bacterial pneumonia risk.

This study was supported by grants from the US National Institutes of Health (K12 RR023247, U01 AI042170, U01 AI046362, U01 AI068641, U01 AI068641), the University of New South Wales, and the Minnesota Veterans Medical Research and Education Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

O artigo reúne co-autores do Insight SMART Study Group.

Identificador

Plos One, v. 8. n.2, p. e56249 (8p.), 2013.

http://www.producao.usp.br/handle/BDPI/44015

10.1371/journal.pone.0056249

http://www.plosone.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0056249&representation=PDF

Idioma(s)

eng

Publicador

San Francisco

Relação

PLoS ONE

Direitos

openAccess

Attribution-NonCommercial-NoDerivs 3.0 Brazil

http://creativecommons.org/licenses/by-nc-nd/3.0/br/

Tipo

article

original article

publishedVersion